摘要
急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是血液系统常见的恶性肿瘤性疾病,好发于儿童及青少年,成人ALL约占成人急性白血病的20%~30%。近年来,随着ALL的诊断方法和治疗方案的不断改进,患者治疗后的完全缓解(complete remission,CR)率和长期总体生存(overall survival,OS)率均有了较大程度的提高,然而,在现实临床工作中许多患者仍不可避免地出现疾病复发。目前,针对难治和复发ALL(relapsed/refractory ALL,R/R ALL)患者的治疗仍然是临床中面临的一大难题。我国与欧美发达国家在治疗理念和策略上差异不大,即使经过挽救治疗,中国患者在治疗效果上和欧美国家相比仍有差距。随着我国在新药审评的改革不断深入,中国患者有机会更快地用上创新药物。此外,我们同样应重视针对疾病发病机制及耐药机制的研究,寻找更加有效的治疗靶点和治疗方法,推进适合中国患者的临床试验,进一步改善中国患者的预后。
Acute lymphoblastic leukemia(ALL)is a common malignant tumor disease in the blood system,which occurs in children and adolescents. Adult ALL accounts for about 20%-30% of adult acute leukemia. In recent years,with the continuous improvement of the diagnosis and treatment of ALL,the rate of complete remission(CR)and the rate of overall survival(OS)of patients after treatment have been greatly improved. However,in practical clinical work,many patients still inevitably have disease recurrence. At present,the treatment of refractory ALL(relapsed/refractory ALL(R/R ALL)patients is still a major clinical problem. There is little difference in treatment concepts and strategies between China and developed countries in Europe and America. Even after salvage treatment,there is still a gap between Chinese patients and those in Europe and America. With the deepening reform of new drug evaluation in China,Chinese patients have the opportunity to use innovative drugs more quickly. In addition,we should also pay attention to the research of disease pathogenesis and drug resistance mechanism,find more effective therapeutic targets and methods,promote clinical trials suitable for Chinese patients,and further improve the prognosis of Chinese patients.
作者
王建祥
WANG Jian-xiang(Blood Disease Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2021年第4期283-290,共8页
Chinese Journal of Practical Internal Medicine
关键词
急性淋巴细胞白血病
难治
复发
治疗
acute lymphoblastic leukemia
relapsed
refractory
treatment
